Popular Articles
Revitol Cellulite Cream

Tiller Murder Prompts Abortion Providers To Re-Evaluate Protective Measures, Security
The recent murder of Kansas abortion provider George Tiller has prompted other providers nationwide to reassess their need for protective measures against violent actions from opponents of abortion rights, the AP/San Francisco Chronicle reports. In the days following Tiller"s murder, many clinic officials nationwide said that they had contacted law enforcement and examined their existing security measures. U.S. Attorney General Eric Holder also ordered the U.S. Marshals Service to provide security to several clinicians and facilities. According to the AP/Chronicle, violence against abortion providers in the 1980s and 1990s forced many to take various precautionary measures in and around their clinics, while some underwent training to protect themselves.Kate Michelman, former president of NARAL Pro-Choice America, said the election of former President George W. Bush, an abortion-rights opponent, helped alleviate some violence against abortion providers. However, she said that she believes Tiller"s murder might indicate the situation is changing during the first months of President Obama"s administration. Obama has rejected abortion-rights opponents" calls for restrictions on the procedure and also reversed the "global gag rule," or "Mexico City" policy.Michelman said, "Historically, when those who oppose a woman"s right to decide are frustrated politically, they get more violent," adding, "I have been thinking about this ever since the [Obama] election." She said that some providers will remain fearful even though she believes clinics are now safe. "In the end ... if someone is out to get you and they are determined and have a chorus encouraging them, ... there"s not much you can do to stop them," Michelman said. Provider LeRoy Carhart, who provided abortion services at Tiller"s clinic, said that people who commit violence against abortion providers should be charged with hate crimes (Hanna, AP/San Francisco Chronicle, 6/3). Don't forget to buy zoloft online no prescription.

New Jersey Senate, Assembly Panels Advance Autism Coverage Bill
Committees in the New Jersey Senate and Assembly on Monday unanimously approved a bill that would provide insurance benefits of up to $36,000 annually for autism treatments, the Philadelphia Inquirer reports. The funding, provided to developmentally disabled individuals younger than age 21, would go toward diagnostic services and early behavioral intervention, as well as occupational, physical and speech therapies. The Assembly could vote on the bill as early as Thursday, while the Senate bill is being considered by the state Senate Budget and Appropriations Committee.Sen. Loretta Weinberg (D), who sponsored the Senate bill, said, "I don"t know of any parent who wouldn"t do everything in their power to give their autistic or developmentally disabled child every chance to excel. However, the enormous cost of behavior intervention ... makes it out of the realm of possibility for many families." Assembly Speaker Joseph Roberts (D), who sponsored the Assembly bill, said, "In this economy, every New Jersey resident is struggling, but families with kids with special needs are struggling even more," adding, "They"re maxing out their credit cards and taking out second mortgages" to cover gaps in health insurance benefits.Citing cost issues, the New Jersey Business and Industry Association and the New Jersey Association of Health Plans were among those opposed to the bill. Christine Stearns, NJBIA vice president for health and legal affairs, said that the bill would make employer-sponsored insurance more costly and cause firms to drop such coverage, adding, "How, who and what is part of a basic health plan is all part of that." Stearns added that the bill is preferable to previous versions because it mandates that covered services be medically necessary and prescribed, places a reasonable cap on prices and ensures that the cost of educational services provided by schools is not shifted to insurers. Roberts said the bill would save money by delivering earlier treatment that could prevent more costly problems in the future (Henry, Philadelphia Inquirer, 5/19).

generic viagra online


News of the day
Sotomayor's Record Contradicts Conservatives' Claims Of Radicalism, Washington Post Columnist Writes
"If Sonia Sotomayor is a radical activist eager to push the law leftward or to rule according to personal whims rather than constitutional commands, she"s done an impressive job of hiding it all these years," Washington Post columnist Ruth Marcus writes, adding that the "amazing thing about the case against Sotomayor is how thin it is." She writes, "If Sotomayor is the judicial radical of conservative imaginings, certainly there ought to be something more in her paper trail."Marcus continues that an "examination of Sotomayor"s decisions shows a careful judge who tends to rule for the government over criminal defendants; who has been skeptical of most civil rights claims that have come before her; and who, to the extent that she has ruled on cases that touch on abortion, has come down against the abortion-rights side." According to Marcus, Sotomayor is "not apt to be David Souter in reverse -- a Democratic pick who turns out to be a close conservative." However, there also is "no evidence that she will be outside the liberal mainstream on the current court," Marcus writes. Marcus notes that Sotomayor "has ruled in favor of abortion protesters who claimed police used excessive force in removing them from outside a clinic," and she "refused to overturn the federal policy barring international family planning funds to organizations that perform or promote abortion," known as the "global gag rule." Marcus concludes, "Perhaps Sotomayor the radical has been biding her time, awaiting the day when the freedom of a Supreme Court seat would liberate her from precedent and moderation," but "the record suggests" that outcome is "unlikely" (Marcus, Washington Post, 6/3).
Oncology

Investigational Cancer Drug BSI-201 Showed Clinical Benefit In 62% Of Patients With Triple-Negative Metastatic Breast Cancer

Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) and its fully owned subsidiary, BiPar Sciences, today announced results from a randomized Phase 2 clinical trial of BSI-201, a poly ADP-ribose polymerase (PARP) inhibitor, in combination with gemcitabine and carboplatin (GC) chemotherapy, in patients with metastatic triple-negative breast cancer (TNBC). BSI-201 is a novel investigational agent that acts by inhibiting PARP1, an enzyme that repairs DNA damage. In this study, 116 women with metastatic TNBC, defined as tumors lacking expression of estrogen and progesterone receptors and without overexpression of HER2, were randomly assigned to receive GC in combination with the investigational agent BSI-201 or GC alone. Patients assigned to receive chemotherapy without BSI-201 were allowed to receive BSI-201 at the time of disease progression. The primary study endpoint was the rate of clinical benefit, defined as complete or partial response or stable disease of at least 6 months. Secondary study endpoints included progression-free survival, overall survival and safety. Approximately 62 percent of patients receiving BSI-201 in combination with GC showed clinical benefit, compared with 21 percent in the group receiving chemotherapy alone (p= 0.0002). Tumor response (complete or partial response) was observed in 48 percent of patients who received BSI-201 combined with chemotherapy, whereas patients receiving chemotherapy alone showed a response rate of 16 percent. Women who received BSI-201 had a median progression-free survival of 6.9 months and overall survival of 9.2 months compared with 3.3 and 5.7 months, respectively, for women who received chemotherapy alone. The hazard ratios for progression free survival and overall survival were 0.342 (p About BSI-201 Among other investigational PARP inhibitors in the industry, BSI-201 is the furthest along in clinical development in metastatic TNBC. BSI-201 is currently being evaluated for its potential to enhance the effect of chemotherapy-induced DNA damage. The clinical development of BSI-201 is supported by well documented safety profile based on studies of more than 200 patients. About TNBC When patients are diagnosed with breast cancer, their tumors are routinely tested for the presence of estrogen and progesterone receptors and for the over-expression of HER2. Commonly used breast cancer therapies target these receptors; for example, tamoxifen for estrogen receptor and trastuzumab (Herceptin(r)) for HER2. However, 15-20% of all breast cancers lack over-expression of all three proteins, thus giving rise to the term "triple- negative breast cancer" or "TNBC." TNBC can be an aggressive disease, with higher rates of metastases and poorer survival rates than other breast cancer subtypes. No treatment has been approved specifically for TNBC. Sanofi-aventis


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):